Scinai Immunotherapeutics (SCNI) Research & Development (2014 - 2026)
Scinai Immunotherapeutics (SCNI) posted Research & Development of -$628000.0 for Q1 2026, down 1182.76% sequentially from $58000.0 in Q2 2025, and up 51.51% YoY from -$414505.6 in Q1 2025.
Scinai Immunotherapeutics (SCNI) Research & Development (2014 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Research & Development for 13 years, with the latest figure at -$628000.0 in Q1 2026.
- Quarterly Research & Development rose 51.51% year-over-year to -$628000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$528000.0 (up 90.77% YoY) and the FY2025 annual result came in at -$2.4 million, down 142.82% from the prior year.
- Research & Development slipped to -$628000.0 in Q1 2026 per SCNI's latest filing, from $58000.0 in the prior quarter.
- Over five years, Research & Development peaked at $9.8 million in Q4 2023 and troughed at -$4.4 million in Q2 2024.
- A 5-year average of $1.0 million and a median of $1.2 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 582.91% in 2023, then tumbled 399.59% in 2024.
- Over 5 years, Research & Development stood at $1.4 million in 2022, then surged by 582.91% to $9.8 million in 2023, then tumbled by 86.35% to $1.3 million in 2024, then sank by 95.66% to $58000.0 in 2025, then slumped by 1182.76% to -$628000.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$628000.0, $58000.0, and -$1.3 million for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | -628,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -628,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Mar 31, 2025 | -1.30 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -4.36 Mn |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 9.79 Mn |
| Sep 30, 2023 | 1.13 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.97 Mn |
| Mar 31, 2022 | 1.16 Mn |
| Dec 31, 2021 | -3.43 Mn |
| Sep 30, 2021 | 2.02 Mn |
| Jun 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 825,000.00 |
| Dec 31, 2020 | 7.87 Mn |